Anti-BCMA CAR /NFAT (Luciferase) Reporter Jurkat Cell Line

SKU:BHC18200203
Research Validated
Overview
Click light‑blue chips for details
Anti-BCMA CAR /NFAT (Luciferase) Reporter Jurkat Cell Line is a CAR-T Cell Line (Jurkat (clone E6-1) background, Human origin, BSL-1) from BPS Bioscience. Designed for • predict the moa of the car design
• measurements of antibody (scfv-car) specificity • screen and validate bcma-expressing caner target cells workflows.
Parental Cell Line Jurkat (clone E6-1)
Species Human
Biosafety Level BSL-1
Product Type CAR-T Cell Line
Mycoplasma Tested Confirmed Negative
Storage Liquid Nitrogen
Options selector
Catalog no. Size
79694 2 Vials
Available Options

Select the variant that best fits your experiment. Availability and lead time may vary by option.

  • Options: Size: 2 Vials
  • Lead time: options listed in "Availability Content"; other statuses may take longer.
  • Storage: Immediately upon receipt, store in liquid nitrogen.
  • Shipping: cold-chain shipment (typically with ice packs).
  • Upon receipt: store at the recommended temperature as soon as possible.
  • Sales terms and conditions: Please review prior to ordering.
Field Specification
Mfr No 79694
Alternative Names tumor necrosis factor receptor superfamily member 17, B-Cell Maturation Antigen, TNFRSF17, CD28, T-cell receptor zeta, 4-1BB, CD137
Product Type
  • CAR-T Cell Line
Shipping -80°C (dry ice)
Species Human
Storage Immediately upon receipt, store in liquid nitrogen.

Scientific Background

The development of CAR-T cells is a complex process that requires I) screening and sequencing of mAbs that are specific to the cancer antigens; II) synthesis of scFv cDNA and clone into Chimeric Antigen Receptor (CAR) cassette in Lentivector (e.g. anti-BCMA scFv in 3rd generation CAR cassette in lentivector); III) packaging and production of high titer lentivirus CAR encoding lentivirus; IV) isolation, activation and expansion of patient-derived T cells that exhibit a specific cellular phenotype (e.g. CD4+ or CD8+ or a mix); V) and transduction of activated T cells with CAR-encoding lentivirus; VI) Validation of engineered CAR-T cells through FACS and functional analysis. BPS has developed an anti-BCMA CAR Jurkat/NFAT-luciferase stable reporter cell line, it is one of a series of reporter bioassays using CAR-T Lentivirus and Jurkat/NFAT-luciferase reporter cell lines. The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a great system to predict the mechanism of action (MOA) and therapeutic potential of the anti-BCMA CAR lentivirus before using it with patient-derived primary T cells. It is a single cell clonal stable cell line developed by transducing the Jurkat/NFAT-Luciferase reporter cells with the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701).

Product Description

CAR-T

The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a stable cell line made from the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701). It has been validated for anti BCMA-CAR expression by FACS, and for functional activation stimulated by both soluble BCMA protein (BPS Bioscience #79467) and BCMA/CHO target cells (BPS Bioscience #79500).

Product Specifications

Host Cell Line Jurkat (clone E6-1)
Host Species Human t lymphoblast, suspension
Transfection Method Lentivirus, BPS# 79701
Supplied As Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO and 90% FBS
Harmonized Tariff Code 3002-5900

Quality Control & Validation

✓ Mycoplasma-Tested

The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species.

Usage Notes

See assay protocol for detailed instructions.

Regulatory Information

License RequiredYes
Living Modified OrganismYes

License Disclosure

License Disclosure Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact sales@bpsbioscience.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.

Related Products

Related Products: Cat. #60690, 60184, 79500, 79701, 79796, 79784

Required Accessories: Cat. #60184,79784,79796,60690

What is the parental cell line for this product?

This product is engineered on a Jurkat (clone E6-1) background (Human origin). The Jurkat (clone E6-1) host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.

What biosafety level is required for this cell line?

This product is classified as BSL-1. Standard microbiological practices (gloves, lab coat, eye protection) are sufficient. No specialized containment facility is required beyond a clean bench. Consult your institutional IBC for GMO registration requirements.

Has this cell line been tested for mycoplasma contamination?

Yes. The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.

What are the recommended storage conditions?

Store this product at Liquid Nitrogen. Specifically: Immediately upon receipt, store in liquid nitrogen. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.

Is a license required to use this product?

Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.

What method was used to generate this cell line?

This stable cell line was generated using Lentivirus, BPS# 79701 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.

Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:

  • Cell line sourcing and selection (species, tissue, and disease model matching)
  • Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
  • Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
  • Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
  • Inducible expression systems (Tet-On/Off and regulatable constructs)
  • Drug resistance marker selection (puromycin, G418, hygromycin, and others)
  • Custom growth and media optimisation for specific assay requirements
  • Scale-up production for high-throughput screening campaigns
  • Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)

Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.

  1. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Wang et. al. J Hematol Oncol. 2019 Jun 11;12(1):59
  2. Chimeric antigen receptor T cell therapy for multiple myeloma. Hasegawa et.al. Inflamm Regen. 2019 Jun 4;39:10.
  3. Novel targets for the treatment of relapsing multiple myeloma. Giuliani et. al. Expert Rev Hematol. 2019 Jun 3:1-16.
  4. Anti-BCMA antibodies in the future management of multiple myeloma. Gavriatopoulou et. al. Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326.
Matches this product
15%OFF
15% Off Cancer Antibodies
Ends Sep 30 ONCO15
Matches this product
10% OFF
10% OFF CELL LINES-Limited-Time Offer
Ends Sep 30 CELL10
$50 OFF
$50 Off All ELISA Kits
Limited time ELISA50
FREE SAMPLE
Free Sample – CellTrypase Recombinant Trypsin-Like Enzyme
Limited time offer – availa... FREESAMPLE
FREE SAMPLE
Free Sample – MycoFold™ Growth Factors
Limited time offer – availa... Request Free Sample

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today